KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Other Operating Expenses: 2019-2025

Historic Other Operating Expenses for Castle Biosciences (CSTL) over the last 5 years, with Sep 2025 value amounting to $21.0 million.

  • Castle Biosciences' Other Operating Expenses rose 17.33% to $21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $105.8 million, marking a year-over-year increase of 61.57%. This contributed to the annual value of $71.3 million for FY2024, which is 32.07% up from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Other Operating Expenses is $21.0 million, which was up 7.11% from $19.6 million recorded in Q2 2025.
  • Castle Biosciences' 5-year Other Operating Expenses high stood at $44.7 million for Q1 2025, and its period low was -$10.6 million during Q2 2022.
  • In the last 3 years, Castle Biosciences' Other Operating Expenses had a median value of $16.8 million in 2024 and averaged $19.1 million.
  • In the last 5 years, Castle Biosciences' Other Operating Expenses spiked by 1,397.35% in 2021 and then plummeted by 368.53% in 2022.
  • Over the past 5 years, Castle Biosciences' Other Operating Expenses (Quarterly) stood at $5.6 million in 2021, then soared by 104.01% to $11.4 million in 2022, then increased by 28.50% to $14.7 million in 2023, then spiked by 39.67% to $20.5 million in 2024, then rose by 17.33% to $21.0 million in 2025.
  • Its last three reported values are $21.0 million in Q3 2025, $19.6 million for Q2 2025, and $44.7 million during Q1 2025.